These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 6102461)

  • 1. Bromocriptine and CF 25-397 in the treatment of tardive dyskinesia.
    Tamminga CA; Chase TN
    Arch Neurol; 1980 Apr; 37(4):204-5. PubMed ID: 6102461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Therapeutic measures in tardive dyskinesia].
    Tegeler J; Wöller W
    Fortschr Neurol Psychiatr; 1983 Jun; 51(6):203-26. PubMed ID: 6136457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of tardive dyskinesia with bromocriptine. A test of the receptor modification strategy.
    Lieberman JA; Alvir J; Mukherjee S; Kane JM
    Arch Gen Psychiatry; 1989 Oct; 46(10):908-13. PubMed ID: 2572205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bromocriptine in tardive dyskinesia.
    Häggström JE; Andersson U; Gunne LM
    Pharmacopsychiatria; 1982 Sep; 15(5):161-3. PubMed ID: 6129649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Dopamine-receptor stimulators and neuroleptic-induced dyskinesia (author's transl)].
    Ringwald E
    Pharmakopsychiatr Neuropsychopharmakol; 1978 Nov; 11(6):294-8. PubMed ID: 33397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical activity of GABA agonists in neuroleptic- and L-dopa-induced dyskinesia.
    Morselli PL; Fournier V; Bossi L; Musch B
    Psychopharmacology Suppl; 1985; 2():128-36. PubMed ID: 2860656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroleptic malignant syndrome superimposed on tardive dyskinesia.
    Haggerty JJ; Bentsen BS; Gillette GM
    Br J Psychiatry; 1987 Jan; 150():104-5. PubMed ID: 2888500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The behavioral toxicity of bromocriptine in patients with psychiatric illness.
    Perovich RM; Lieberman JA; Fleischhacker WW; Alvir J
    J Clin Psychopharmacol; 1989 Dec; 9(6):417-22. PubMed ID: 2574194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ergot derivatives for Parkinsonism.
    Calne DB; Williams AC; Nutt JG; Neophytides A; Eisler T; Teychenne PF
    Med J Aust; 1978 Nov; 2(3 Suppl):25-6. PubMed ID: 34083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Use and value of the therapeutic neuroleptic-bromocriptine combination in schizophrenia].
    Lombertie ER; Durelle G; Fuseau A
    Ann Med Psychol (Paris); 1995 Oct; 153(8):531-4. PubMed ID: 8561400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metoclopramide and haloperidol in tardive dyskinesia.
    Bateman DN; Dutta DK; McClelland HA; Rawlins MD
    Br J Psychiatry; 1979 Dec; 135():505-8. PubMed ID: 43755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of Schizophrenia with ergot derivatives.
    Tamminga CA; Schaffer MH
    Psychopharmacology (Berl); 1979; 66(3):239-42. PubMed ID: 119270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tardive dyskinesia: clinical and neuroendocrine response to low dose bromocriptine.
    Lenox RH; Weaver LA; Saran BM
    J Clin Psychopharmacol; 1985 Oct; 5(5):286-92. PubMed ID: 4044881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxprenolol in schizophrenic patients with tardive dyskinesia: a double-blind placebo-controlled, crossover study.
    Karniol IG; Portela W
    Braz J Med Biol Res; 1982 Dec; 15(6):389-94. PubMed ID: 6135468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison between lergotrile and bromocriptine in parkinsonism.
    Teychenne PF; Pfeiffer RF; Bern SM; McInturff D; Calne DB
    Ann Neurol; 1978 Apr; 3(4):319-24. PubMed ID: 666273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic strategies against tardive dyskinesia. Two decades of experience.
    Jeste DV; Wyatt RJ
    Arch Gen Psychiatry; 1982 Jul; 39(7):803-16. PubMed ID: 6131655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clonazepam and phenobarbital in tardive dyskinesia.
    Bobruff A; Gardos G; Tarsy D; Rapkin RM; Cole JO; Moore P
    Am J Psychiatry; 1981 Feb; 138(2):189-93. PubMed ID: 6109454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of the dopamine agonists bromocriptine and cabergoline in the management of risperidone-induced hyperprolactinemia in patients with psychotic disorders.
    Tollin SR
    J Endocrinol Invest; 2000 Dec; 23(11):765-70. PubMed ID: 11194712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Occurrence of tardive dyskinesia during neuroleptic treatment].
    Fanget F; Henry E; Aimard G
    Presse Med; 1986 Dec; 15(43):2147-50. PubMed ID: 2884657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement in tardive dyskinesia after muscimol therapy.
    Tamminga CA; Crayton JW; Chase TN
    Arch Gen Psychiatry; 1979 May; 36(5):595-8. PubMed ID: 35117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.